Menelas N Pangalos bought $255K of Absci (ABSI)
Executed Sep 22 2025, disclosed Sep 24 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 24 2025), the stock returned +62.6% (delay-adjusted); from the execution session (Sep 22 2025), +82.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Menelas N Pangalos (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Absci Corporation (ABSI). Across 3 priced purchase filings, the average 21-session return was +34.6% from execution and +32.3% from disclosure (delay-adjusted; derived). The largest single filing was $255K of ABSI (95,785 sh × $2.66, as filed), executed Sep 22 2025.
Healthcare · Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→37,453 sh × $5.36
Exec May 13
Filed May 13 · 4:05 PM ET ABSIPURCHASE Absci Corporation $206K
75,095 sh × $2.74
Exec Feb 27
Filed Mar 3 · 4:13 PM ET